Navigation Links
'Normalizing' tumor vessels leaves cancer more benign
Date:2/12/2009

A report publishing online on February 12th in the journal Cell, a Cell Press publication, suggests a counterintuitive new method to make cancer less likely to spread: by normalizing the shape of tumors' blood vessels to improve their oxygen supply. Such a treatment strategy might also boost the efficacy and reduce resistance to available anti-cancer drugs and so-called anti-angiogenic drugs that work by cutting off the growth of new blood vessels.

"In tumors, the endothelial cells lining blood vessels grow in all directions and over each other," said Peter Carmeliet of Vesalius Research Center. Irregular shape and gaps left in the vessel walls also make them leaky.

Tissues need oxygen delivered by the bloodstream to grow. But, in the case of tumors, that haphazard overgrowth of blood vessels and deteriorated endothelial lining impairs their own ability to function, he continued. As a result, tumors become more and more oxygen deprived a condition that is a "driving force" for cancer cells to escape and spread to other parts of the body.

That vicious cycle might be halted with treatments designed to target an oxygen-sensing enzyme known as PHD2 in the linings of tumors' blood vessels, Carmeliet's team now finds. The new results also offer fundamental new insight into blood vessel biology.

Indeed, numerous earlier studies had examined how blood vessels arise, branch and elongate at the molecular level. However, little was known about how vessels regulate their shape.

Since supply of oxygen is one of the most basic functions of vessels, the researchers also suspected that they should possess ways to sense and re-adapt oxygen supply in the case of a shortage. They looked to a newly discovered class of oxygen sensors: the prolyl hydroxylase domain proteins, PHD1-3.

In the current study, Carmeliet's group focused on the role of PHD2 in balancing oxygen levels by influencing the characteristics of blood vessels. In mice with half the
'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Study identifies another strategy for normalizing tumor blood supply
2. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
3. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
4. Study details regulation of vital tumor suppressor gene p53
5. Human C-reactive protein regulates myeloma tumor cell growth and survival
6. Customized virus kills brain tumor stem cells that drive lethal cancer
7. Study suggests brain tumors need treatment with multiple targeted drugs
8. Bright tumors, dim prospects
9. National Brain Tumor Foundation Unites with BrainLAB in Support of Patient Education
10. Discovery of widespread tumor growth gene holds promise for effective anti-cancer treatment
11. PET scans can accurately detect a breast tumors response to chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2015)... San Mateo, CA (PRWEB) May 03, 2015 ... newest service, MnemeTherapy® at two upcoming area seminars. The ... during the PSA Annual Regional Stroke Conference to be ... will be offered on Wednesday, May 13 during the ... Crowne Plaza. , “These seminars offer an excellent ...
(Date:5/3/2015)... May 03, 2015 HealthPostures, a ... solutions, announces its appearance at the , May 5 ... that HealthPostures will exhibit at the conference include its ... sit stand solutions is the 6100 TaskMate Executive. Features ... control, an adjustable keyboard tray, extended platform work surface ...
(Date:5/2/2015)... BC (PRWEB) May 02, 2015 Vancouver fencing ... will now provide valuable advice to prospective clients related to ... are looking to install railings around their decks and patios. ... several questions that pop up once the person rolls up ... phases of installing a railing in finding a gate that ...
(Date:5/2/2015)... NY (PRWEB) May 02, 2015 It’s ... a deadly natural disaster strikes anywhere on this planet, ... leverage human sympathy and compassion for their own personal ... States Computer Emergency Readiness Team) issued an alert ... “of potential email scams citing the earthquake in Nepal. ...
(Date:5/2/2015)... 02, 2015 On Tuesday April 7th, ... (ELCH) gathered to celebrate improvements in patient care. In ... Partners (RVHP), had zero acquired ventilator associated infections, zero ... infections. ELCH was also recently named a Top Performer ... at ELCH credited the teamwork of staff from all ...
Breaking Medicine News(10 mins):Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2
... Carbon monoxide poisoning is a serious threat, especially during the ... keep warm, says the American College of Emergency Physicians. ... precautionary steps or notice the symptoms. Thinking about it now ... may save your life and the lives of those around ...
... , MONDAY, Dec. 27 (HealthDay News) -- ... heart rhythms that can cause heart damage and sudden ... worldwide and found variants in 22 locations across the ... measure of electrical depolarization in the heart,s lower chambers ...
... potential therapy based on a natural human protein significantly slows ... same genetic mutation as boys with the most common form ... 27 in the Proceedings of the National Academy of ... mutation in about one of every 3,500 boys. They are ...
... from the University of Pennsylvania School of Medicine and Utrecht ... branch of the immune response. This system, called complement, comprises ... in destroying foreign invaders. It serves as a rapid defense ... In a study published in the December 24 issue of ...
... , SATURDAY, Dec. 25 (HealthDay News) -- For allergy sufferers ... relief from respiratory symptoms, an expert suggests. Dust from ... plants and more can cause all sorts of breathing problems, ... in Melrose Park, Ill. In a news release from Loyola ...
... By Dennis Thompson HealthDay Reporter , MONDAY, Dec. ... that she had cataracts in both eyes. "They saw them ... surgery then," Norred, now 74 and living in Oklahoma City, recalled. ... both eyes in the spring -- the right eye on May ...
Cached Medicine News:Health News:Carbon Monoxide May Be Greater Threat in Winter 2Health News:Human protein improves muscle function of muscular dystrophy mice 2Health News:Structure of key molecule in immune system provides clues for designing drugs 2Health News:Structure of key molecule in immune system provides clues for designing drugs 3Health News:Have an Allergy-Free Holiday and a Happier New Year 2Health News:Have Cataracts? Get Surgery, Woman Urges 2
(Date:5/1/2015)...  Thoratec Corporation (NASDAQ: THOR ), a world leader ... failing hearts, announced today that Marta Antonucci has ... This new Europe -based position ... North America , including Europe ... America , and reports directly to the Chief Executive ...
(Date:5/1/2015)... May 1, 2015 Braeburn Pharmaceuticals ... current therapeutic focus beyond addiction and pain ... disorders. Braeburn has acquired an implantable, six-month ... risperidone for treatment of schizophrenia from Endo ... global rights to other potential applications of ...
(Date:5/1/2015)... 2015 Pharmacyclics, Inc. (the "Company") (NASDAQ: ... ended March 31, 2015, as well as general business ... conference call will be held. Key Highlights ... 31, 2015 increased to $206 million from $119 million ... Worldwide IMBRUVICA ® (ibrutinib) net product revenue of ...
Breaking Medicine Technology:Thoratec Announces Addition To Senior Management Team 2Thoratec Announces Addition To Senior Management Team 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 5Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 6Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 7Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 8Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 9Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 10Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 12Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 13Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 14Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 15Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 16Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 17Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 18Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 19Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 20Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 21Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 22Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 23Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 24Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 25Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 26Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 27Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 28Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 29Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 30Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 31
... Onset and Total,Sleep Time, and key secondary endpoints, including ... Evotec to host a,conference call at 4pm CET (3pm ... OXFORD, England, June 4, 2007-- Evotec AG,(Frankfurt Stock Exchange: ... II clinical trial of EVT 201 in,patients with chronic ...
... Placebo-controlled Trial,Ever Conducted in CTCL Presented at ... 04, 2007 /PRNewswire/ -- Preliminary results of,the ... patients with cutaneous T-cell lymphoma (CTCL) showed,that ... as placebo in eliciting,a clinical response in ...
Cached Medicine Technology:Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 2Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 3Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 4Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 2Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 3Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 4Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 5Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 6
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: